Carl Zeiss Meditec AG reaffirmed earning guidance for 2022. The Company's outlook for fiscal year 2021/22 remains unchanged: Revenue is expected to grow at least to the same extent as the market.
Market Closed -
Other stock markets
|
After market 03:15:46 pm | |||
66.05 EUR | +0.84% |
|
66.15 | +0.15% |
Jun. 19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | ![]() |
Jun. 18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.17% | 6.29B | |
+5.00% | 217B | |
+7.29% | 191B | |
+27.54% | 154B | |
+33.42% | 112B | |
+1.22% | 62.75B | |
+18.56% | 53.34B | |
+1.45% | 48.88B | |
-4.06% | 39.36B | |
+3.31% | 35.73B |
- Stock Market
- Equities
- AFX Stock
- News Carl Zeiss Meditec AG
- Carl Zeiss Meditec AG Reaffirms Earning Guidance for 2022